RxDoctor Payments Data

Mary Colburn, APRN

Family · Wallingford, CTNPI 1679066948

Payments from drug & device makers

$7,681in general payments, 2019–2025

Across 477 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Scilex Pharmaceuticals Inc.$1K
  • AbbVie$918
  • Valinor Pharma, LLC$918
  • ANI Pharmaceuticals, Inc.$390
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$7,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,681 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$64,913
Medicare patients
102
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl120$131,641
Xtampza ErOxycodone Myristate130$93,883
MovantikNaloxegol Oxalate194$82,802
RelistorMethylnaltrexone Bromide15$38,249
Nurtec OdtRimegepant Sulfate20$37,831
LinzessLinaclotide60$35,056
UbrelvyUbrogepant14$22,993
HorizantGabapentin Enacarbil27$22,393
NucyntaTapentadol Hcl25$19,946
BelbucaBuprenorphine Hcl24$19,802
Oxycodone Hcl997$19,585
GraliseGabapentin16$14,372
ZtlidoLidocaine11$12,065
Buprenorphine48$9,711
Aimovig AutoinjectorErenumab-Aooe13$9,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Belbuca$1,488$133,632179 claims
AbbVieLinzess, Ubrelvy$918$58,05074 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,278$38,24915 claims
PfizerNurtec Odt$282$37,83120 claims
Almatica Pharma LLCGralise$110$14,37216 claims
Scilex Pharmaceuticals Inc.Ztlido$1,110$12,06511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →